Topic Hub

Dpp4 Inhibitors — Drug Class Monograph

3 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.

3articles

31keywords mapped

2026-05-27latest review

Explore

Dpp4 Inhibitors — Drug Class Monograph library

Showing 3 of 3 clinical reviews.

Clinical Reviews2026-05-27

DPP-4 Inhibitor Adverse-Event Management: Clinical Protocols for Prescribers

Evidence-based protocols for identifying, grading, and managing adverse events associated with DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) in type 2 diabetes.

Read clinical review

Clinical Reviews2026-05-27

DPP-4 Inhibitors Class Overview Monograph

A clinician-level monograph covering the DPP-4 inhibitor drug class: mechanism, pharmacokinetics, CV outcomes trials, renal dosing, place in therapy, and prescribing guidance for sitagliptin, saxagliptin, linagliptin, alogliptin, and vildagliptin.

Read clinical review

Dosing & Monitoring2026-05-27

DPP-4 Inhibitors Monitoring Bundle: Labs, Timelines, and Clinical Checkpoints

A prescriber-level guide to the monitoring bundle for DPP-4 inhibitors (gliptins), covering baseline labs, follow-up intervals, renal dose adjustments, and safety surveillance for sitagliptin, saxagliptin, linagliptin, and alogliptin.

Read clinical review